Edward Broun, MD
Hematology & Oncology · Cincinnati, OHNPI 1295728459
Payments from drug & device makers
Across 57 payments — averaging $8851.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$303K
- AbbVie$159K
- PTC Therapeutics, Inc.$32K
- Karyopharm Therapeutics Inc.$8K
- E.r. Squibb & Sons, L.L.C.$2K
- Fresenius Kabi USA, LLC$630
- plus $397 from 6 others
Across 4 payments — averaging $1582.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6K
What the payments were for
- Consulting fees$2,60687%
- Food & beverage$38613%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $303,368 |
| AbbVie | 19 | $158,637 |
| PTC Therapeutics, Inc. | 7 | $31,680 |
| Karyopharm Therapeutics Inc. | 7 | $7,875 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,976 |
| Fresenius Kabi USA, LLC | 2 | $630 |
| Pharmacyclics LLC, An Abbvie Company | 12 | $266 |
| Gilead | 1 | $50 |
| Aurobindo Pharma USA, Inc. | 2 | $37 |
| Johnson & Johnson | 1 | $18 |
| Bristol Myers Squibb | 1 | $15 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Stimufend$630
How this compares
$504,563 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 16 | $315 |
| Fluconazole | 12 | $188 |
| Levofloxacin | 16 | $87 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cincinnati
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- David WaterhouseCincinnati$5.7M
- Patrick WardCincinnati$3.8M
- James EssellCincinnati$3.7M
- Edward FaberCincinnati$2.3M
- Omar AlkharabshehCincinnati$1.2M
- Alexander StarodubCincinnati$1.1M
- Mark JohnsCincinnati$999K
- Jason JonesCincinnati$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.